Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

The NHS says: “You should only use weight management medicines if a doctor or pharmacist recommends them for you. They will ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

Certain foods and drinks could produce comparable effects to GLP-1 inhibitors, according to research ...

He cited one study, which found an average a return to baseline weight in around 1.5 years after taking the medications.

In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as ...

FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.

Research found that certain natural compounds could impact your appetite ...

Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital ...

Corxel Pharmaceuticals Ltd. completed a $287 million series D round to advance its lead compound, an oral small-molecule GLP-1 receptor agonist, CX-11, for obese and overweight patients. Headquartered ...